RAC1 and head and neck squamous cell carcinoma: Lastly, based on our findings that G-box-clustering mutations of RAC1 would impact both tumorigenic activity and the clinical outcomes of HNSCC, the development of a new class of inhibitors for some of these G-box mutants, in particular, A159V, may be clinically important as well.